SBIR Phase I: Using patient specific DNA methylation to predict COVID-19 clinical prognosis

SBIR 第一阶段：利用患者特异性 DNA 甲基化来预测 COVID-19 临床预后

• 批准号: 2034014
• 负责人: Kristin Brogaard
• 金额: $ 25.6万
• 依托单位: INHERENT BIOSCIENCES, INC.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-01 至 2021-09-30
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2034014&HistoricalAwards=false
• 关键词: SBIR; Phase; Using; patient; specific

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is the development of an onsite, clinical test to screen incoming patients potentially infected with COVID-19 and prioritize hospital resources and personnel based on a predicted infection severity and treatment response. The benefits of a test that can predict COVID-19 infection severity are enormous. In addition to the millions of infections and hundreds of thousands of dealths, it costs hospitals an average of roughly $2,500 per day per patient for inpatient care. This project will develop a test for COVID-19 screening to accurately identify patients at risk. This Small Business Innovation Research (SBIR) Phase I project is establishing the use of DNA methylation patterns for personalized screening and treatment for COVID-19. The variation in symptoms and outcomes for COVID-19 progression make it challenging for healthcare workers to triage accurately. The development of a DNA methylation-based test to predict the severity of COVID-19 infection will help manage the pandemic. This project will: 1) generate a comprehensive dataset of white blood cell DNA methylation patterns, health history, and clinical data for patients infected with COVID-19; 2) generate a predictive model for COVID-19 infection severity and treatment response. The anticipated technical results of this project are a testing method and a computer algorithm for predicting infection severity and treatment response based on a patient’s unique DNA methylation pattern.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这项小型企业创新研究（SBIR）第一阶段项目的更广泛影响/商业潜力是开发现场临床测试，以筛查可能感染COVID-19的患者，并根据预测的感染严重程度和治疗反应优先考虑医院资源和人员。可以预测COVID-19感染严重程度的测试的好处是巨大的。除了数以百万计的感染和数十万的交易外，医院平均每位患者每天的住院治疗费用约为2,500美元。该项目将开发COVID-19筛查测试，以准确识别风险患者。这个小企业创新研究（SBIR）第一阶段项目正在建立DNA甲基化模式用于COVID-19的个性化筛查和治疗。2019冠状病毒病进展的症状和结果的变化使医疗工作者难以准确分类。 开发基于DNA甲基化的测试来预测COVID-19感染的严重程度将有助于控制大流行。该项目将：1）生成COVID-19感染患者的白色血细胞DNA甲基化模式、健康史和临床数据的综合数据集; 2）生成COVID-19感染严重程度和治疗反应的预测模型。该项目的预期技术成果是一种测试方法和一种计算机算法，用于根据患者独特的DNA甲基化模式预测感染严重程度和治疗反应。该奖项反映了NSF的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。